Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 66.7%Low 2 · 33.3%Moderate 0 · 0%High 0 · 0%

HALOPERIDOL vs first‐generation antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).

1 finding from 1 review

Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
RR 0.93 [0.4, 2.16]
13 studies · 507 participants
Very low

Haloperidol discontinuation vs haloperidol continuation

Satisfaction with treatment: leaving the study early Endpoint data (events) · schizophrenia

It is very uncertain whether haloperidol discontinuation changes satisfaction with treatment: leaving the study early compared with haloperidol continuation (very low certainty).

1 finding from 1 review

Haloperidol discontinuation for people with schizophrenia 2019 · Cochrane Headline outcomes only
RR 0.13 [0.01, 2.28]
1 study · 43 participants
Very low

HALOPERIDOL vs first‐generation antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).

1 finding from 1 review

Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
RR 1.04 [0.87, 1.24]
28 studies · 1299 participants
Low

HALOPERIDOL vs first‐generation antipsychotics

Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia

It is very uncertain whether haloperidol changes leaving the study early due to adverse events as a measure of… compared with first‐generation antipsychotics (very low certainty).

1 finding from 1 review

Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
RR 1 [0.42, 2.35]
16 studies · 640 participants
Very low

HALOPERIDOL vs first‐generation antipsychotics

Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia

It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).

1 finding from 1 review

Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
RR 1.02 [0.75, 1.38]
2 studies · 137 participants
Very low

HALOPERIDOL vs first‐generation antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

1 finding from 1 review

Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Low